CAS 1118567-05-7

Formule : C24H29ClO7

InChI : InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1

Code InChI : BTCRKOKVYTVOLU-SJSRKZJXSA-N

SMILES : C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl

Bexagliflozin

CAS : 1118567-05-7

Bexagliflozin

Formule : C₂₄H₂₉ClO₇

Degré de pureté : ≥98%

Masse moléculaire : 464.94

Ref: 54-BUP03804

Bexagliflozin

CAS : 1118567-05-7

Formule : C₂₄H₂₉ClO₇

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 464.9359

Ref: IN-DA008TOL

Bexagliflozin

Produit contrôlé

CAS : 1118567-05-7

Formule : C₂₄H₂₉ClO₇

Couleur et forme : Neat

Masse moléculaire : 464.94

Ref: TR-B336785

Bexagliflozin

CAS : 1118567-05-7

Formule : C₂₄H₂₉ClO₇

Masse moléculaire : 464.94

Ref: 4Z-B-295001

Bexagliflozin

CAS : 1118567-05-7

Bexagliflozin (EGT1442) is a potent, selective sodium glucose co-transporter 2 (SGLT2) inhibitor with IC50 values of 2 nM for human SGLT2.

Formule : C₂₄H₂₉ClO₇

Degré de pureté : 98.99% - 99.89%

Couleur et forme : Solid

Masse moléculaire : 464.936

Ref: TM-T7217

Bexagliflozin

CAS : 1118567-05-7

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Formule : C₂₄H₂₉ClO₇

Degré de pureté : 98%

Masse moléculaire : 464.94

Ref: IN-DG629906

BEXAGLIFLOZIN

CAS : 1118567-05-7

Degré de pureté : 99%

Masse moléculaire : 464.9400024

Ref: 10-F799844

Bexagliflozin

CAS : 1118567-05-7

Bexagliflozin is a drug that is used to treat type II diabetes in adults. It helps to control blood sugar levels by inhibiting the enzyme DPP-IV and increasing insulin release from the pancreas. Bexagliflozin has been shown to be effective in lowering blood sugar levels in patients with chronic kidney disease and cancer, as well as those with a body mass index (BMI) of 30 or higher. This drug is an oral hypoglycaemic agent that can be used for diagnostic purposes. It has also been shown to be clinically effective for the treatment of diabetic nephropathy and diabetic retinopathy. The enantiomers of bexagliflozin can be differentiated according to their pharmacological properties, which may allow for more targeted therapy.

Formule : C₂₄H₂₉ClO₇

Degré de pureté : Min. 95%

Masse moléculaire : 464.94 g/mol

Ref: 3D-FA145137

Bexagliflozin

CAS : 1118567-05-7

Formule : C₂₄H₂₉ClO₇

Masse moléculaire : 464.94

Ref: ST-EA-CP-B168000